AzTrials
AzTrials

EpilepsyNCT02497105

Ketogenic Diet Program for Epilepsy

A study testing Ketogenic Diet in people with Epilepsy, run by Shriners Hospitals for Children at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study will assess the effectiveness of the ketogenic diet (high-fat, low-carbohydrate, and moderate protein) in treating epilepsy. Two study groups will be comprised of children with epilepsy (0-18 years of age) and whether or not they receive the ketogenic diet - epilepsy/ketogenic diet and… Read more about this study

Who is it for?
Ages 6 months to 18 yearsHealthy volunteers can take part
Conditions the study is for
Epilepsy
What is being tested?
Ketogenic Diet
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteUnited States
Study dates
Jan 2015to 19 Jan 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 months to 18 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult

Who may be able to join

  • Ages 0-18 years.
  • Primary diagnosis of epilepsy.
  • Parent/legal guardian and child able to read or understand English, and able/willing to provide informed consent/assent.
  • Females of childbearing potential must have a negative pregnancy test result and agree to use a medically acceptable method of contraception throughout the entire study period and for 30 days after the last dose of study drug - childbearing potential is defined a girls who are > Tanner stage 2 and urine pregnancy tests are acceptable.

Who cannot join

  • Known cardiac disorder including arrhythmias or hypertension.
  • Carnitine deficiency (primary).
  • Carnitine palmitoyltransferase (CPT) I or II deficiency.
  • Carnitine translocase deficiency.
  • Beta-oxidation defects - medium-chain acyl dehydrogenase deficiency (MCAD), long-chain acyl dehydrogenase deficiency (LCAD), short-chain acyld dehydrogenase deficiency (SCAD), long-chain 3-hydroxyacyl-coenzyme A (CoA) deficiency, and medium-chain 3-hydroxyacyl-CoA deficiency.
  • Pyruvate carboxylase deficiency.
Show all 9Show fewer
  • Porphyria.
  • Inability to maintain adequate nutrition.
  • Patient or caregiver non-compliance.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Shriners Hospitals for Children - Honolulu

    Honolulu, Hawaii, 96826-1099

Other trials in United States

About this study

This study will assess the effectiveness of the ketogenic diet (high-fat, low-carbohydrate, and moderate protein) in treating epilepsy. Two study groups will be comprised of children with epilepsy (0-18 years of age) and whether or not they receive the ketogenic diet - epilepsy/ketogenic diet and epilepsy/non-ketogenic diet.

Read the detailed description

According to an evidence-based guideline on the diagnosis and management of epilepsy from the National Institute for Clinical Excellence (2012), the ketogenic diet may be considered as an adjunctive treatment in children with drug-resistant epilepsy. Vast anecdotal and Class 1 studies have confirmed that the ketogenic diet helps most children with intractable seizures and cures many. Dietary therapies for epilepsy (e.g., classic ketogenic diet) have been shown to be highly effective. For example, Lee (P.R.) and Kossoff reported that approximately 50% of children with drug-resistant epilepsy had a greater than 50% reduction in seizures within days to months of treatment. In addition, use of the ketogenic diet as a treatment for epilepsy has been shown to reduce the escalating costs associated managing poorly controlled seizures (e.g., decrease in outpatient and emergency visits, inpatient hospitalization, neuroimaging, electro-encephalography, lab testing, and medication use).

If a child's seizures continue after two to three seizure medications have been tried, the ketogenic diet should be considered. However, many parents still medicate their children well beyond these guidelines and tolerate seizure frequency because they have no other alternatives. Given the physical and emotional toll that recurring seizures exact upon these children/families, the potential for improvement with the ketogenic diet is substantial. However, the ketogenic diet remains unavailable to most children.

Approximately 1% of Hawaii's children are projected to have epilepsy, but there is no established, ketogenic diet program for them to receive this dietary intervention, which can incorporate culturally distinct foods to improve palatability and compliance. Although the ketogenic diet has shown promise for broadening the scope of therapeutic options for children with epilepsy, it requires further study in an ethnically diverse population. At Shriners Hospitals for Children-Honolulu, the investigators have initiated a ketogenic and related dietary (e.g., modified Atkins diet) intervention program for children with epilepsy and started to assess its efficacy in treating epilepsy/seizures. This program also includes educational seminars and services to patients residing on the other Hawaii islands through outreach trips. The investigators have begun to enroll children with epilepsy into two groups based on whether or not they receive the ketogenic diet - epilepsy/ketogenic diet and epilepsy/non-ketogenic diet; total estimate of 15-30 participants over three years. Based upon initial findings, the investigators will implement a comprehensive, multidisciplinary ketogenic diet program that will potentially reach hundreds of children throughout Hawaii, the Pacific Basin, and elsewhere.

Specific Aims:

Aim 1. To assess the therapeutic efficacy of the ketogenic diet on epilepsy/seizures.

Hypothesis: Participants who have epilepsy/on the ketogenic diet will have significantly decreased number and severity of seizures than those that are not on the ketogenic diet, between baseline to three and six months after the dietary intervention is initiated.

Aim 2. In anticipation of lessened epilepsy/seizures, to determine the (a) change in number and dose of seizure medications used, (b) change in number of lab tests ordered for epilepsy management, (c) change in number of emergency room and hospital visits for seizures (or other neurodevelopmental problems), (d) change in number of neurologic procedures for epilepsy management (e.g. EEG, MRI, CT), and (e) participant/family satisfaction with the ketogenic diet.

Hypothesis: The number and/or dosage of medications, lab tests ordered, emergency room or hospital visits, and neurologic procedures for epilepsy management will decrease, and participant/family satisfaction will be high for participants who have epilepsy/on the ketogenic diet than those that are not on the ketogenic diet, between baseline to three and six months after the dietary intervention is initiated.

Aim 3. To compare differences and/or changes in (a) serum and urine ketone levels and (b) biochemical profiles as defined from blood and stool (gut or fecal microbiome) specimen samples.

Hypothesis: Participants who have epilepsy/on the ketogenic diet will have significantly higher serum/urine ketone levels and notably different biochemical profiles than those that are not on the ketogenic diet, between baseline to three and six months after the dietary intervention is initiated.

Children helped by the ketogenic diet are more likely to reach their highest level of functioning and become contributing adults. By providing the ketogenic diet as an intervention therapy for epilepsy in a safe and data-driven manner, the community-at-large will benefit and medical knowledge concerning dietary treatment for neurodevelopmental disorders will be advanced.

Conditions
Epilepsy
Being tested
Ketogenic Diet
Keywords
Epilepsy, Intractable Seizures, Ketogenic Diet, Biochemical Profiles
Medical subject headings
Epilepsy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ketogenic DietOther

    Dietary

Study groups in NCT02497105
Study groupRoleWhat they receive
Epilepsy/Ketogenic DietExperimentalChildren (0-18 years of age) diagnosed with epilepsy will receive the ketogenic diet intervention.
Receives: Other: Ketogenic Diet
Epilepsy/Non-Ketogenic DietNo interventionChildren (0-18 years of age) diagnosed with epilepsy will not receive the ketogenic diet intervention.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from baseline in the core symptoms of epilepsy (seizure frequency/severity)

    Assess the number of epileptic seizures through review/analysis of responses to the seizure log (self-report)

    Measured: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet)

Secondary outcomes (7)
  1. Change from baseline in the number of medications used for epilepsy management

    Assess changes through the review/analysis of self-report and medical record data

    Measured: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet)

  2. Change from baseline in the dosage of medications used for epilepsy management

    Assess changes through the review/analysis of self-report and medical record data

    Measured: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet)

  3. Change from baseline in the number of lab tests ordered for epilepsy management

    Assess changes through the review/analysis of self-report and medical record data

    Measured: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet)

  4. Change from baseline in the number of emergency room or hospital visits for epilepsy management

    Assess changes through the review/analysis of self-report and medical record data

    Measured: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet)

  5. Change from baseline in subject/family satisfaction with the ketogenic diet

    Assess changes through the review/analysis of self-report and medical record data

    Measured: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet)

  6. Change from baseline in ketone levels due to the ketogenic diet

    Assess ketone level differences and changes through the analysis of serum and urine

    Measured: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet)

  7. Change from baseline in biochemical profiles due to the ketogenic diet

    Assess biochemical profile differences and changes through the analysis of blood and stool (gut microbiome) specimen samples

    Measured: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Jul 2015 (estimated)
  2. Study startJan 2015
  3. Primary completion19 Jan 2018
  4. Study completion19 Jan 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02497105
Sponsor's protocol ID
HON1402
Status last verified
Sep 2019
First submitted
9 Jul 2015
Last updated
20 Sep 2019
Results posted
No
Data monitoring committee
Yes
Individual data sharing
No

Publications

  • http://www.aetna.com/cpb/medical/data/200_299/0226.html Clinical Policy Bulletin: Hospitalization for the Initiation of Ketogenic Diet for the Treatment of Intractable Seizures. Accessed November 14, 2013.

  • Cervenka MC, Kossoff EH. Dietary treatment of intractable epilepsy. Continuum (Minneap Minn). 2013 Jun;19(3 Epilepsy):756-66. doi: 10.1212/01.CON.0000431396.23852.56.

    PubMed 23739109
  • National Clinical Guideline Centre (UK). The Epilepsies: The Diagnosis and Management of the Epilepsies in Adults and Children in Primary and Secondary Care: Pharmacological Update of Clinical Guideline 20. London: Royal College of Physicians (UK); 2012 Jan. Available from http://www.ncbi.nlm.nih.gov/books/NBK247130/

    PubMed 25340221
  • http://www.charliefoundation.org/offering-hope.html Accessed November 14, 2013

  • Lee PR, Kossoff EH. Dietary treatments for epilepsy: management guidelines for the general practitioner. Epilepsy Behav. 2011 Jun;21(2):115-21. doi: 10.1016/j.yebeh.2011.03.008. Epub 2011 Apr 21.

    PubMed 21514240
  • Williams E, Abrahams J, Maguire A, Harris G. A parent's perspective on dietary treatments for epilepsy. Epilepsy Res. 2012 Jul;100(3):338-43. doi: 10.1016/j.eplepsyres.2011.09.024. Epub 2012 May 8.

    PubMed 22575229
  • Kossoff EH, Caraballo RH, du Toit T, Kim HD, MacKay MT, Nathan JK, Philip SG. Dietary therapies: a worldwide phenomenon. Epilepsy Res. 2012 Jul;100(3):205-9. doi: 10.1016/j.eplepsyres.2011.05.024.

    PubMed 21856128
  • Gilbert DL, Pyzik PL, Vining EP, Freeman JM. Medication cost reduction in children on the ketogenic diet: data from a prospective study. J Child Neurol. 1999 Jul;14(7):469-71. doi: 10.1177/088307389901400712.

    PubMed 10573471
  • Mandel A, Ballew M, Pina-Garza JE, Stalmasek V, Clemens LH. Medical costs are reduced when children with intractable epilepsy are successfully treated with the ketogenic diet. J Am Diet Assoc. 2002 Mar;102(3):396-8. doi: 10.1016/s0002-8223(02)90091-x.

    PubMed 11902372
  • Vining EP, Freeman JM, Ballaban-Gil K, Camfield CS, Camfield PR, Holmes GL, Shinnar S, Shuman R, Trevathan E, Wheless JW. A multicenter study of the efficacy of the ketogenic diet. Arch Neurol. 1998 Nov;55(11):1433-7. doi: 10.1001/archneur.55.11.1433.

    PubMed 9823827
  • Freeman JM, Vining EP, Pillas DJ, Pyzik PL, Casey JC, Kelly LM. The efficacy of the ketogenic diet-1998: a prospective evaluation of intervention in 150 children. Pediatrics. 1998 Dec;102(6):1358-63. doi: 10.1542/peds.102.6.1358.

    PubMed 9832569
  • Neal EG, Chaffe H, Schwartz RH, Lawson MS, Edwards N, Fitzsimmons G, Whitney A, Cross JH. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol. 2008 Jun;7(6):500-6. doi: 10.1016/S1474-4422(08)70092-9. Epub 2008 May 2.

    PubMed 18456557
  • Henderson CB, Filloux FM, Alder SC, Lyon JL, Caplin DA. Efficacy of the ketogenic diet as a treatment option for epilepsy: meta-analysis. J Child Neurol. 2006 Mar;21(3):193-8. doi: 10.2310/7010.2006.00044.

    PubMed 16901419
  • Beghi E, Frigeni B, Beghi M, De Compadri P, Garattini L. A review of the costs of managing childhood epilepsy. Pharmacoeconomics. 2005;23(1):27-45. doi: 10.2165/00019053-200523010-00003.

    PubMed 15693726
  • de Kinderen RJ, Lambrechts DA, Postulart D, Kessels AG, Hendriksen JG, Aldenkamp AP, Evers SM, Majoie MH. Research into the (Cost-) effectiveness of the ketogenic diet among children and adolescents with intractable epilepsy: design of a randomized controlled trial. BMC Neurol. 2011 Jan 25;11:10. doi: 10.1186/1471-2377-11-10.

    PubMed 21262002

Questions about this trial

What is this clinical trial studying?

A study testing Ketogenic Diet in people with Epilepsy, run by Shriners Hospitals for Children at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 Sep 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from baseline in the core symptoms of epilepsy (seizure frequency/severity) (time frame: Pre- and post-ketogenic diet intervention (at baseline, and after three and six months on the ketogenic diet)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02497105, which also lists 19 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Sep 2019.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Ketogenic Diet Program for Epilepsy (NCT02497105) | AzTrials